Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Opioid-induced constipation: a narrative review of therapeutic options in clinical management.

The Korean journal of pain

Lang-Illievich K, Bornemann-Cimenti H.
PMID: 31091505
Korean J Pain. 2019 Apr 01;32(2):69-78. doi: 10.3344/kjp.2019.32.2.69.

Pain therapy often entails gastrointestinal adverse events. While opioids are effective drugs for pain relief, the incidence of opioid-induced constipation (OIC) varies greatly from 15% to as high as 81%. This can lead to a significant impairment in quality...

Cite
Lang-Illievich K, Bornemann-Cimenti H. Opioid-induced constipation: a narrative review of therapeutic options in clinical management. Korean J Pain. 2019;32(2):69-78doi: 10.3344/kjp.2019.32.2.69.
Lang-Illievich, K., & Bornemann-Cimenti, H. (2019). Opioid-induced constipation: a narrative review of therapeutic options in clinical management. The Korean journal of pain, 32(2), 69-78. https://doi.org/10.3344/kjp.2019.32.2.69
Lang-Illievich, Kordula, and Bornemann-Cimenti, Helmar. "Opioid-induced constipation: a narrative review of therapeutic options in clinical management." The Korean journal of pain vol. 32,2 (2019): 69-78. doi: https://doi.org/10.3344/kjp.2019.32.2.69
Lang-Illievich K, Bornemann-Cimenti H. Opioid-induced constipation: a narrative review of therapeutic options in clinical management. Korean J Pain. 2019 Apr 01;32(2):69-78. doi: 10.3344/kjp.2019.32.2.69. PMID: 31091505; PMCID: PMC6549585.
Copy Download .nbib Format: NLM
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.

CNS spectrums

Yagoda S, Graham C, Simmons A, Arevalo C, Jiang Y, McDonnell D.
PMID: 32393412
CNS Spectr. 2021 Aug;26(4):383-392. doi: 10.1017/S1092852920001376. Epub 2020 May 12.

BACKGROUND: Combination olanzapine and samidorphan (OLZ/SAM), in development for schizophrenia and bipolar I disorder, is intended to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM safety, tolerability, and efficacy from a 52-week open-label extension study in...

Cite
Yagoda S, Graham C, Simmons A, et al. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS Spectr. 2020;26(4):383-392doi: 10.1017/S1092852920001376.
Yagoda, S., Graham, C., Simmons, A., Arevalo, C., Jiang, Y., & McDonnell, D. (2021). Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS spectrums, 26(4), 383-392. https://doi.org/10.1017/S1092852920001376
Yagoda, Sergey, et al. "Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study." CNS spectrums vol. 26,4 (2021): 383-392. doi: https://doi.org/10.1017/S1092852920001376
Yagoda S, Graham C, Simmons A, Arevalo C, Jiang Y, McDonnell D. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS Spectr. 2021 Aug;26(4):383-392. doi: 10.1017/S1092852920001376. Epub 2020 May 12. PMID: 32393412.
Copy Download .nbib Format: NLM
Enteral tolerance in critically ill patients.

Journal of intensive care

Tatsumi H.
PMID: 31086671
J Intensive Care. 2019 May 07;7:30. doi: 10.1186/s40560-019-0378-0. eCollection 2019.

Enteral nutrition (EN) can maintain the structure and function of the gastrointestinal mucosa better than parenteral nutrition. In critically ill patients, EN must be discontinued or interrupted, if gastrointestinal complications, particularly vomiting and bowel movement disorders, do not resolve...

Cite
Tatsumi H. Enteral tolerance in critically ill patients. J Intensive Care. 2019;7:30doi: 10.1186/s40560-019-0378-0.
Tatsumi, H. (2019). Enteral tolerance in critically ill patients. Journal of intensive care, 730. https://doi.org/10.1186/s40560-019-0378-0
Tatsumi, Hiroomi. "Enteral tolerance in critically ill patients." Journal of intensive care vol. 7 (2019): 30. doi: https://doi.org/10.1186/s40560-019-0378-0
Tatsumi H. Enteral tolerance in critically ill patients. J Intensive Care. 2019 May 07;7:30. doi: 10.1186/s40560-019-0378-0. eCollection 2019. PMID: 31086671; PMCID: PMC6505301.
Copy Download .nbib Format: NLM
Opioids regulate cGMP formation in cloned neuroblastoma cells.

Proceedings of the National Academy of Sciences of the United States of America

Gwynn GJ, Costa E.
PMID: 16593149
Proc Natl Acad Sci U S A. 1982 Jan;79(2):690-4. doi: 10.1073/pnas.79.2.690.

Opioid agonists caused a rapid dose-related elevation of the cGMP content of N4TG1 murine neuroblastoma cells. An excellent correlation was found between the rank order of potency of agonists in stimulating cGMP accumulation and in displacing [(3)H]etorphine ([(3)H]ETP) bound...

Cite
Gwynn GJ, Costa E. Opioids regulate cGMP formation in cloned neuroblastoma cells. Proc Natl Acad Sci U S A. 1982;79(2):690-4doi: 10.1073/pnas.79.2.690.
Gwynn, G. J., & Costa, E. (1982). Opioids regulate cGMP formation in cloned neuroblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 79(2), 690-4. https://doi.org/10.1073/pnas.79.2.690
Gwynn, G J, and Costa, E. "Opioids regulate cGMP formation in cloned neuroblastoma cells." Proceedings of the National Academy of Sciences of the United States of America vol. 79,2 (1982): 690-4. doi: https://doi.org/10.1073/pnas.79.2.690
Gwynn GJ, Costa E. Opioids regulate cGMP formation in cloned neuroblastoma cells. Proc Natl Acad Sci U S A. 1982 Jan;79(2):690-4. doi: 10.1073/pnas.79.2.690. PMID: 16593149; PMCID: PMC345812.
Copy Download .nbib Format: NLM
The promise, problems and limitations of methadone: a clinical perspective.

Journal of clinical forensic medicine

White AP.
PMID: 16371275
J Clin Forensic Med. 1994 Sep;1(2):97-104. doi: 10.1016/1353-1131(94)90008-6.

The use, advantages, disadvantages and side-effects of methadone are described. Outcome studies are reviewed. It is suggested that there is no good scientific evidence that dispensing methadone to non-compliant patients is an effective intervention. This is supported by studies...

Cite
White AP. The promise, problems and limitations of methadone: a clinical perspective. J Clin Forensic Med. 1994;1(2):97-104doi: 10.1016/1353-1131(94)90008-6.
White, A. P. (1994). The promise, problems and limitations of methadone: a clinical perspective. Journal of clinical forensic medicine, 1(2), 97-104. https://doi.org/10.1016/1353-1131(94)90008-6
White, A P. "The promise, problems and limitations of methadone: a clinical perspective." Journal of clinical forensic medicine vol. 1,2 (1994): 97-104. doi: https://doi.org/10.1016/1353-1131(94)90008-6
White AP. The promise, problems and limitations of methadone: a clinical perspective. J Clin Forensic Med. 1994 Sep;1(2):97-104. doi: 10.1016/1353-1131(94)90008-6. PMID: 16371275.
Copy Download .nbib Format: NLM
Acute Myocardial Infarction following Naltrexone Consumption; a Case Report.

Emergency (Tehran, Iran)

Dadpour B, Gholoobi A, Tajoddini S, Habibi A.
PMID: 28286852
Emerg (Tehran). 2017;5(1):e45. Epub 2017 Jan 14.

Cardiovascular effects of opioid withdrawal have long been studied. It was reported that patients with underlying ischemic heart disease and atherosclerotic vessels may be complicated by a sudden physical and emotional stress due to withdrawal syndrome. But some other...

Cite
Dadpour B, Gholoobi A, Tajoddini S, et al. Acute Myocardial Infarction following Naltrexone Consumption; a Case Report. Emerg (Tehran). 2017;5(1):e45
Dadpour, B., Gholoobi, A., Tajoddini, S., & Habibi, A. (2017). Acute Myocardial Infarction following Naltrexone Consumption; a Case Report. Emergency (Tehran, Iran), 5(1), e45.
Dadpour, Bita, et al. "Acute Myocardial Infarction following Naltrexone Consumption; a Case Report." Emergency (Tehran, Iran) vol. 5,1 (2017): e45.
Dadpour B, Gholoobi A, Tajoddini S, Habibi A. Acute Myocardial Infarction following Naltrexone Consumption; a Case Report. Emerg (Tehran). 2017;5(1):e45. Epub 2017 Jan 14. PMID: 28286852; PMCID: PMC5325916.
Copy Download .nbib Format: NLM
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

EC psychology and psychiatry

Blum K, Modestino EJ, Badgaiyan RD, Baron D, Thanos PK, Elman I, Siwicki D, Febo M, Gold MS.
PMID: 30417173
EC Psychol Psychiatr. 2018 Aug;7(8):564-579. Epub 2018 Jul 30.

Blum's laboratory first showed the benefits of naloxone or narcotic antagonists in the treatment of alcohol dependence. This seminal work published in Nature in the early 70's, in conjunction with many other studies, later served as the basis for...

Cite
Blum K, Modestino EJ, Badgaiyan RD, et al. Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse. EC Psychol Psychiatr. 2018;7(8):564-579
Blum, K., Modestino, E. J., Badgaiyan, R. D., Baron, D., Thanos, P. K., Elman, I., Siwicki, D., Febo, M., & Gold, M. S. (2018). Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse. EC psychology and psychiatry, 7(8), 564-579.
Blum, Kenneth, et al. "Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse." EC psychology and psychiatry vol. 7,8 (2018): 564-579.
Blum K, Modestino EJ, Badgaiyan RD, Baron D, Thanos PK, Elman I, Siwicki D, Febo M, Gold MS. Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse. EC Psychol Psychiatr. 2018 Aug;7(8):564-579. Epub 2018 Jul 30. PMID: 30417173; PMCID: PMC6226033.
Copy Download .nbib Format: NLM
Research on narcotic antagonists.

Science (New York, N.Y.)

Bergner L.
PMID: 17779390
Science. 1971 Dec 10;174(4014):1079. doi: 10.1126/science.174.4014.1079.

No abstract available.

Cite
Bergner L. Research on narcotic antagonists. Science. 1971;174(4014):1079doi: 10.1126/science.174.4014.1079.
Bergner, L. (1971). Research on narcotic antagonists. Science (New York, N.Y.), 174(4014), 1079. https://doi.org/10.1126/science.174.4014.1079
Bergner, L. "Research on narcotic antagonists." Science (New York, N.Y.) vol. 174,4014 (1971): 1079. doi: https://doi.org/10.1126/science.174.4014.1079
Bergner L. Research on narcotic antagonists. Science. 1971 Dec 10;174(4014):1079. doi: 10.1126/science.174.4014.1079. PMID: 17779390.
Copy Download .nbib Format: NLM
Intravenous narcotic antagonists in ambulatory oral surgery.

Anesthesia progress

Greenfield W, Granada MG.
PMID: 19598479
Anesth Prog. 1975 Mar;22(2):38-44.

Results of a study indicate that significant respiratory depression can be produced by the intravenous administration of narcotics in the anesthetic management of oral surgery patients. Naloxone hydrochloride reversed this reaction in all instances. Naloxone is a unique narcotic...

Cite
Greenfield W, Granada MG. Intravenous narcotic antagonists in ambulatory oral surgery. Anesth Prog. 1975;22(2):38-44
Greenfield, W., & Granada, M. G. (1975). Intravenous narcotic antagonists in ambulatory oral surgery. Anesthesia progress, 22(2), 38-44.
Greenfield, W, and Granada, M G. "Intravenous narcotic antagonists in ambulatory oral surgery." Anesthesia progress vol. 22,2 (1975): 38-44.
Greenfield W, Granada MG. Intravenous narcotic antagonists in ambulatory oral surgery. Anesth Prog. 1975 Mar;22(2):38-44. PMID: 19598479; PMCID: PMC2235666.
Copy Download .nbib Format: NLM
Naltrexone-associated Visual Hallucinations: A Case Report.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Lee DB, Woo YS, Bahk WM.
PMID: 30905136
Clin Psychopharmacol Neurosci. 2019 May 31;17(2):329-331. doi: 10.9758/cpn.2019.17.2.329.

Naltrexone is a competitive antagonist of Μ, δ, and κ opioid receptors. Naltrexone has been investigated for use an as anti-obesity agent in both the general population and in patients with severe mental illness, including schizophrenia. In patients with...

Cite
Lee DB, Woo YS, Bahk WM. Naltrexone-associated Visual Hallucinations: A Case Report. Clin Psychopharmacol Neurosci. 2019;17(2):329-331doi: 10.9758/cpn.2019.17.2.329.
Lee, D. B., Woo, Y. S., & Bahk, W. M. (2019). Naltrexone-associated Visual Hallucinations: A Case Report. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 17(2), 329-331. https://doi.org/10.9758/cpn.2019.17.2.329
Lee, Dae Bo, et al. "Naltrexone-associated Visual Hallucinations: A Case Report." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 17,2 (2019): 329-331. doi: https://doi.org/10.9758/cpn.2019.17.2.329
Lee DB, Woo YS, Bahk WM. Naltrexone-associated Visual Hallucinations: A Case Report. Clin Psychopharmacol Neurosci. 2019 May 31;17(2):329-331. doi: 10.9758/cpn.2019.17.2.329. PMID: 30905136; PMCID: PMC6478085.
Copy Download .nbib Format: NLM
First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis.

The Journal of emergency medicine

Peacock WF, Slatkin NE, Israel RJ, Stambler N.
PMID: 34893381
J Emerg Med. 2021 Dec 07; doi: 10.1016/j.jemermed.2021.10.012. Epub 2021 Dec 07.

BACKGROUND: Opioid-induced constipation (OIC) is a frequent consequence of opioid analgesia that may increase patient risk for emergency department visits and hospitalization. Methylnaltrexone is a peripherally acting µ-opioid receptor antagonist indicated for the treatment of OIC.OBJECTIVE: To assess the...

Cite
Peacock WF, Slatkin NE, Israel RJ, et al. First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis. J Emerg Med. 2021;doi: 10.1016/j.jemermed.2021.10.012.
Peacock, W. F., Slatkin, N. E., Israel, R. J., & Stambler, N. (2021). First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis. The Journal of emergency medicine, . https://doi.org/10.1016/j.jemermed.2021.10.012
Peacock, W Frank, et al. "First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis." The Journal of emergency medicine vol. (2021). doi: https://doi.org/10.1016/j.jemermed.2021.10.012
Peacock WF, Slatkin NE, Israel RJ, Stambler N. First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis. J Emerg Med. 2021 Dec 07; doi: 10.1016/j.jemermed.2021.10.012. Epub 2021 Dec 07. PMID: 34893381.
Copy Download .nbib Format: NLM
Narcotic antagonists.

Science (New York, N.Y.)

Baden MM.
PMID: 17847189
Science. 1972 Sep 29;177(4055):1152. doi: 10.1126/science.177.4055.1152-a.

No abstract available.

Cite
Baden MM. Narcotic antagonists. Science. 1972;177(4055):1152doi: 10.1126/science.177.4055.1152-a.
Baden, M. M. (1972). Narcotic antagonists. Science (New York, N.Y.), 177(4055), 1152. https://doi.org/10.1126/science.177.4055.1152-a
Baden, M M. "Narcotic antagonists." Science (New York, N.Y.) vol. 177,4055 (1972): 1152. doi: https://doi.org/10.1126/science.177.4055.1152-a
Baden MM. Narcotic antagonists. Science. 1972 Sep 29;177(4055):1152. doi: 10.1126/science.177.4055.1152-a. PMID: 17847189.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries